Glycine 2-methyl proline glutamate (G-2mPE) is a
proline-modified analogue to the naturally existing N-terminal tripeptide
glycine-proline-glutamate that is a cleaved product from
insulin-like growth factor-1.
G-2mPE is designed to be more enzymatically resistant than
glycine-proline-glutamate and to increase its bioavailability. The current study has investigated the protective effects of
G-2mPE following hypoxic-ischemic
brain injury in the neonatal brain. On postnatal day 7, Wistar rats were exposed to
hypoxia-
ischemia (HI). HI was induced by unilateral
ligation of the left carotid artery followed by
hypoxia (7.7% O2, 36 degrees C) for 60 min. The
drug treatment started 2 h after the insult, and the pups were given either 1.2 mg/kg (bolus), 1.2 mg/ml once a day for 7 days, or vehicle. The degree of brain damage was determined histochemically by
thionin/
acid fuchsin staining. G-2mPE's anti-inflammatory properties were investigated by IL-1beta,
IL-6, and
IL-18 ELISA, and effects on apoptosis by
caspase 3 activity. Vascularization was determined immunohistochemically by the total length of
isolectin-positive blood vessels. Effect on
astrocytosis was also determined in the hippocampus. Animals treated with multiple doses of
G-2mPE demonstrated reduced overall
brain injury 7 days after HI, particularly in the hippocampus and thalamus compared to vehicle-treated rats. The expression of
IL-6 was decreased in G-2mPE-treated animals compared to vehicle-treated pups, and both the capillary length and
astrogliosis were increased in the
drug-treated animals. There was no effect on
caspase 3 activity. This study indicates that peripheral administration of
G-2mPE, starting 2 h after a hypoxic-ischemic insult, reduces the degree of
brain injury in the immature rat brain. The normalization of
IL-6 levels and the promotion of both neovascularization and reactive
astrocytosis may be potential mechanisms that underlie its protective effects.